Plaintiff Alleges Glaxo Hid Avandia Risks

Law360, New York (October 25, 2007, 12:00 AM EDT) -- With regulators pushing for a tougher warning label on GlaxoSmithKline PLC's Avandia, accusations against the pharmaceutical giant are swelling.

The lead plaintiff in one of several proposed class actions accused the company in an amended complaint Wednesday of deliberately concealing the heart attack risks associated with the medication.

Glaxo markets and promotes Avandia as a safe and effective means of enabling the body to utilize naturally secreted insulin and to control blood sugar levels in Type 2 diabetics, Plaintiff Richard V. D'Apuzzo said in his filing...
To view the full article, register now.